Dr. Goy Discusses Single-Agent Ibrutinib in MCL

Andre Goy, MD
Published: Monday, Dec 11, 2017



Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses single-agent ibrutinib (Imbruvica) in mantle cell lymphoma (MCL).

A long-term follow-up of single-agent ibrutinib was presented at the 2017 ASH Annual Meeting. Goy reports that the complete response rate was up to 26%. Additionally, at 3 years, one-quarter of patients still had not progressed.

However, work still needs to be done to determine which patients would benefit best from ibrutinib, Goy adds.
 


Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses single-agent ibrutinib (Imbruvica) in mantle cell lymphoma (MCL).

A long-term follow-up of single-agent ibrutinib was presented at the 2017 ASH Annual Meeting. Goy reports that the complete response rate was up to 26%. Additionally, at 3 years, one-quarter of patients still had not progressed.

However, work still needs to be done to determine which patients would benefit best from ibrutinib, Goy adds.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x